查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1955081

全球出血性疾病检测市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析、未来预测（2026-2034）

Bleeding Disorder Testing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 130 Pages | 商品交期: 请询问到货日

价格

出血性疾病检测市场成长驱动因素

2025年全球出血性疾病检测市场规模为1.098亿美元，2026年成长至1.1839亿美元，预计到2034年将达到2.2338亿美元。 2026年至2034年的复合年增长率（CAGR）为8.26%。欧洲在全球市场中占领先地位，预计到2025年将占40.25%的市场占有率，这得益于其强大的诊断基础设施和较高的疾病认知度。

出血性疾病是指遗传性或后天性疾病，会损害人体正常的血液凝固能力，导致持续性或过度出血。 常见疾病包括A型血友病、B型血友病、血管性血友病（VWD）及特发性血小板减少性紫斑症（ITP）。这些疾病盛行率的不断上升以及诊断平台技术的进步正在推动市场扩张。 市场概览 出血性疾病检测市场的成长主要得益于全球诊断率的提高和医疗服务可近性的改善。根据世界血友病联盟（WFH）统计，2015年至2020年间，出血性疾病的诊断病例数量显着增加，这凸显了人们对该疾病的认识不断提高以及筛检工作的加强。 凝血分析仪自动化、人工智慧 (AI)、机器学习 (ML) 和奈米诊断技术等技术进步正在改变检测流程。例如，罗氏宣布扩展其 cobaspro 整合解决方案的配置，以提高处理能力和效率，从而应对日益增长的诊断需求。

新冠疫情的影响

2020 年，由于就诊量下降和常规诊断测试的推迟，新冠疫情对市场造成了负面影响。由于医疗系统优先进行新冠病毒检测，血友病、血管性血友病及相关疾病的检测数量有所下降。

主要公司的收入出现了暂时性下滑。然而，随着常规医疗服务的恢復，市场在 2021 年和 2022 年开始復苏。随着诊断率的提高和新产品的获批，预计从2025年起市场将持续稳定成长。

市场趋势

人工智慧在诊断的应用

将人工智慧和机器学习（ML）应用于凝血检测是一种新的趋势。人工智慧正被用于预测血友病严重程度、识别基因突变以及提高早期诊断的准确性。此外，旨在提高凝血异常检测灵敏度的奈米诊断技术的研究也不断推进。

在预测期内，研发投入的增加以及与数位医疗的融合预计将加速检测设备和软体平台的创新。

市场成长驱动因素

盛行率和诊断率的上升

出血性疾病在全球盛行率的上升是推动市场成长的主要因素。血友病A仍是最常见的严重遗传性出血性疾病，在全球确诊病例中占相当大的比例。美国国家血友病基金会和世界血友病联盟等组织发布的最新临床指南和进行的宣传活动正在促进早期诊断。

新兴国家医疗基础设施的改善也促进了检测量的增加。

研发投入增加及产品上市

持续的产品创新正在推动市场成长。各公司正在开发先进的止血分析仪和试剂盒，以提高实验室效率和自动化程度。政府支持的针对罕见血液疾病的措施和慈善资助计画正在进一步加速诊断技术的进步。

市场限制因子

儘管成长前景强劲，但市场仍面临诸多挑战，例如新兴市场检测普及率低、诊断指南执行不力以及先进设备和试剂成本高昂。在医疗资源有限的地区，早期诊断仍然困难，这限制了市场扩张。

市场区隔分析

依产品类型

市场依产品类型细分为试剂和耗材以及设备。

  • 试剂和耗材占最大市场占有率（截至2026年为69.34%），预计由于检测频率的增加和持续的需求，其增长速度也将最快。
  • 在凝血分析仪自动化和技术进步的推动下，设备细分市场预计将稳定成长。

依适应症划分

此市场依适应症细分为：血友病A、血管性血友病、血友病B、特发性血小板减少性紫斑症 (ITP) 等。

  • 到2026年，由于血友病A的高发生率和筛检的增加，它将占46.19%的市场占有率。
  • 由于血管性血友病在全球范围内的发生率相对较高，它也占了相当大的市场占有率。

依最终使用者划分

此市场细分为：医院和诊所、诊断中心和其他。

  • 由于病患数量增加和检测设施的完善，到2026年，医院和诊所将占60.31%的市场占有率。
  • 由于自动化分析仪的日益普及，诊断中心预计将拥有最高的复合年增长率。

区域洞察

欧洲

欧洲预计将成为最大的市场，2025 年市场规模为 4,420 万美元，2026 年为 4,775 万美元。该地区受益于健全的监管框架、较高的认知度和完善的诊断指南。

北美

在监管审批和产品上市的支持下，北美预计将显着成长。 2026 年美国市场价值为 2,898 万美元。

亚太及其他地区 (ROW)

中国、日本和印度等新兴市场正在经历医疗保健基础设施的扩张和对罕见疾病认知度的提高。预计到 2026 年，中国市场规模将达到 1,742 万美元，而日本和印度的市场规模预计分别为 385 万美元和 306 万美元。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家出血性疾病盛行率（2025 年）
  • 主要公司新产品上市状况
  • 全球出血性疾病检测市场的技术进步
  • 新冠疫情对市场的影响

第五章 全球出血性疾病检测市场分析：洞察与展望

预测（2021-2034）
  • 市场分析、洞察与预测：依产品类型划分
    • 试剂和耗材
    • 设备
  • 市场分析、洞察与预测：依适应症划分
    • 血友病A
    • 血友病B
    • 血管性血友病
    • 特发性血小板减少性紫斑症（ITP）
    • 其他
  • 市场分析、洞察与预测：依最终用户划分
    • 医院和诊所
    • 诊断中心
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区全球

第六章 北美出血性疾病检测市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲出血性疾病检测市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 其他欧洲地区

第八章 亚太地区出血性疾病检测市场分析：洞察与预测（2021-2034）

  • 国家细分市场
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 其他亚太地区

第九章 其他地区（ROW）出血性疾病检测市场分析：洞察与预测（2021-2034）

第10章 竞争分析

  • 全球市场占有率分析(2025年)
  • 企业简介
    • Siemens Healthcare GmbH
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Atlas Medical GmbH
    • HORIBA, Ltd.
    • Sysmex Corporation
    • HYPHEN BioMed
    • Precision BioLogic Incorporated
    • Other Players
Product Code: FBI106908

Growth Factors of bleeding disorders testing Market

The global bleeding disorders testing market was valued at USD 109.8 million in 2025 and is projected to grow to USD 118.39 million in 2026, reaching USD 223.38 million by 2034, exhibiting a CAGR of 8.26% during 2026-2034. Europe dominated the global market with a 40.25% share in 2025, supported by strong diagnostic infrastructure and high disease awareness.

Bleeding disorders are inherited or acquired conditions that impair the body's ability to clot blood properly, resulting in prolonged or excessive bleeding. Common conditions include Hemophilia A, Hemophilia B, Von Willebrand Disease (VWD), and idiopathic thrombocytopenic purpura (ITP). The increasing prevalence of these disorders, along with technological advancements in diagnostic platforms, is driving market expansion.

Market Overview

The growth of the bleeding disorders testing market is primarily fueled by rising diagnosis rates and improved access to healthcare services globally. According to the World Federation of Hemophilia, the number of diagnosed bleeding disorder cases increased significantly between 2015 and 2020, highlighting growing awareness and screening efforts.

Technological advancements, including automation in coagulation analyzers, artificial intelligence (AI), machine learning (ML), and nano-diagnostics, are transforming testing procedures. For example, Roche launched expanded configurations for its Cobas pro integrated solutions to improve throughput and efficiency, supporting increased diagnostic demand.

COVID-19 Impact

The COVID-19 pandemic negatively affected the market in 2020 due to reduced hospital visits and postponement of routine diagnostic procedures. Testing for hemophilia, Von Willebrand disease, and related conditions declined as healthcare systems prioritized COVID-19 testing.

Major companies experienced temporary revenue declines. However, recovery began in 2021 and 2022 as routine healthcare services resumed. Increased diagnosis rates and new product approvals are expected to sustain steady growth from 2025 onward.

Market Trends

Integration of Artificial Intelligence in Diagnostics

The implementation of AI and ML in coagulation testing is an emerging trend. AI is being explored for predicting hemophilia severity, identifying gene mutations, and enhancing early diagnosis accuracy. Additionally, nano-diagnostic technologies are being studied for improved sensitivity in detecting clotting abnormalities.

Growing R&D investments and digital health integration are expected to accelerate innovation in testing instruments and software platforms during the forecast period.

Market Growth Drivers

Rising Prevalence and Diagnosis Rates

The increasing global prevalence of bleeding disorders is a key growth driver. Hemophilia A remains the most common severe inherited bleeding disorder, accounting for a substantial portion of diagnosed cases worldwide. Updated clinical guidelines and awareness campaigns by organizations such as the National Hemophilia Foundation and the World Federation of Hemophilia are promoting early diagnosis.

Improved healthcare infrastructure in emerging economies is also contributing to higher testing volumes.

Increasing R&D and Product Launches

Continuous product innovation is strengthening market growth. Companies are developing advanced hemostasis analyzers and reagent kits to improve efficiency and automation in laboratories. Government-backed initiatives and philanthropic funding programs aimed at rare blood disorders are further accelerating diagnostic advancements.

Market Restraints

Despite strong growth prospects, the market faces challenges such as low testing penetration in emerging countries, limited adherence to diagnostic guidelines, and high costs of advanced instruments and reagents. In regions with limited healthcare funding, early diagnosis remains a challenge, restricting market expansion.

Segmentation Analysis

By Product Type

The market is segmented into reagents & consumables and instruments.

  • Reagents & consumables held the largest share (69.34% in 2026) and are expected to grow at the fastest rate due to increasing testing frequency and recurring demand.
  • The instruments segment is projected to grow steadily, supported by automation and technological advancements in coagulation analyzers.

By Indication

The market is segmented into Hemophilia A, Von Willebrand Disease, Hemophilia B, ITP, and others.

  • Hemophilia A dominated the market in 2026 with a 46.19% share, driven by high disease prevalence and increased screening.
  • Von Willebrand disease represents a significant segment due to its relatively higher occurrence globally.

By End-user

The market is categorized into hospitals & clinics, diagnostic centers, and others.

  • Hospitals & clinics accounted for 60.31% of the market in 2026, owing to higher patient inflow and established laboratory facilities.
  • Diagnostic centers are expected to witness the highest CAGR due to rising adoption of automated analyzers.

Regional Insights

Europe

Europe led the market with a valuation of USD 44.2 million in 2025 and USD 47.75 million in 2026. The region benefits from strong regulatory frameworks, high awareness levels, and established diagnostic guidelines.

North America

North America is projected to witness significant growth, supported by regulatory approvals and product launches. The U.S. market is valued at USD 28.98 million in 2026.

Asia Pacific and Rest of the World

Emerging economies such as China, Japan, and India are expanding healthcare infrastructure and increasing rare disease awareness. China's market is valued at USD 17.42 million in 2026, while Japan and India are valued at USD 3.85 million and USD 3.06 million in 2026, respectively.

Competitive Landscape

The market is fragmented with key players including F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Sysmex Corporation, HORIBA Ltd., Abbott, Thermo Fisher Scientific Inc., Atlas Medical GmbH, HYPHEN BioMed, and Precision Biologics.

Companies are focusing on product approvals, strategic collaborations, mergers & acquisitions, and expansion of diagnostic portfolios to strengthen their competitive position.

Conclusion

The global bleeding disorders testing market is poised for steady expansion, growing from USD 109.8 million in 2025 to USD 223.38 million by 2034, at a CAGR of 8.26%. Growth is driven by increasing disease prevalence, rising diagnosis rates, technological advancements in coagulation testing, and expanding healthcare infrastructure. Europe currently leads the market, while North America and Asia Pacific are expected to witness substantial growth. Despite challenges such as limited testing penetration in emerging regions, ongoing innovation and awareness initiatives will continue to support long-term market growth through 2034.

Segmentation By Product Type

  • Reagents & Consumables
  • Instruments

By Indication

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Idiopathic Thrombocytopenic Purpura
  • Others

By End-user

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
  • Rest of the World

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Bleeding Disorders, by Key Countries, 2025
  • 4.2. New Product Launches, By Key Players
  • 4.3. Technological Advancements in the Global Bleeding Disorders Testing Market
  • 4.4. Impact of COVID-19 on the Market

5. Global Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Reagents & Consumables
    • 5.1.2. Instruments
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Hemophilia A
    • 5.2.2. Hemophilia B
    • 5.2.3. Von Willebrand Disease
    • 5.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Diagnostic Centers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Reagents & Consumables
    • 6.1.2. Instruments
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Hemophilia A
    • 6.2.2. Hemophilia B
    • 6.2.3. Von Willebrand Disease
    • 6.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Diagnostic Centers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Reagents & Consumables
    • 7.1.2. Instruments
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Hemophilia A
    • 7.2.2. Hemophilia B
    • 7.2.3. Von Willebrand Disease
    • 7.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Diagnostic Centers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. U.K
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Reagents & Consumables
    • 8.1.2. Instruments
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Hemophilia A
    • 8.2.2. Hemophilia B
    • 8.2.3. Von Willebrand Disease
    • 8.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Diagnostic Centers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World Bleeding Disorders Testing Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Reagents & Consumables
    • 9.1.2. Instruments
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Hemophilia A
    • 9.2.2. Hemophilia B
    • 9.2.3. Von Willebrand Disease
    • 9.2.4. Idiopathic Thrombocytopenic Purpura (ITP)
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Diagnostic Centers
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Siemens Healthcare GmbH
      • 10.2.1.1. Overview
      • 10.2.1.2. Product
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. financials (Based on Availability)
    • 10.2.2. F. Hoffmann-La Roche Ltd.
      • 10.2.2.1. Overview
      • 10.2.2.2. Product
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. financials (Based on Availability)
    • 10.2.3. Thermo Fisher Scientific Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Product
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. financials (Based on Availability)
    • 10.2.4. Abbott Laboratories
      • 10.2.4.1. Overview
      • 10.2.4.2. Product
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. financials (Based on Availability)
    • 10.2.5. Atlas Medical GmbH
      • 10.2.5.1. Overview
      • 10.2.5.2. Product
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. financials (Based on Availability)
    • 10.2.6. HORIBA, Ltd.
      • 10.2.6.1. Overview
      • 10.2.6.2. Product
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. financials (Based on Availability)
    • 10.2.7. Sysmex Corporation
      • 10.2.7.1. Overview
      • 10.2.7.2. Product
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. financials (Based on Availability)
    • 10.2.8. HYPHEN BioMed
      • 10.2.8.1. Overview
      • 10.2.8.2. Product
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. financials (Based on Availability)
    • 10.2.9. Precision BioLogic Incorporated
      • 10.2.9.1. Overview
      • 10.2.9.2. Product
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. financials (Based on Availability)
    • 10.2.10. Other Players

List of Tables

  • Table 1: Global Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Product Type, 2021-2034
  • Table 2: Global Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Indication, 2021-2034
  • Table 3: Global Bleeding Disorders Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 4: Global Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 5: North America Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Product Type, 2021-2034
  • Table 6: North America Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Indication, 2021-2034
  • Table 7: North America Bleeding Disorders Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 8: North America Bleeding Disorders Testing Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 9: Europe Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Product Type, 2021-2034
  • Table 10: Europe Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Indication, 2021-2034
  • Table 11: Europe Bleeding Disorders Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 12: Europe Bleeding Disorders Testing Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Product Type, 2021-2034
  • Table 14: Asia Pacific Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Indication, 2021-2034
  • Table 15: Asia Pacific Bleeding Disorders Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 16: Asia Pacific Bleeding Disorders Testing Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Product Type, 2021-2034
  • Table 18: Rest of the World Bleeding Disorders Testing Market Revenue (USD million) Forecast, by Indication, 2021-2034
  • Table 19: Rest of the World Bleeding Disorders Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034

List of Figures

  • Figure 1: Global Bleeding Disorders Testing Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Bleeding Disorders Testing Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global Bleeding Disorders Testing Market Value Share (%), by Indication, 2025 & 2034
  • Figure 4: Global Bleeding Disorders Testing Market Value Share (%), by End-user, 2025 & 2034
  • Figure 5: Global Bleeding Disorders Testing Market Value (USD million), by Region, 2025 & 2034
  • Figure 6: North America Bleeding Disorders Testing Market Value (USD million), by Product Type, 2025 & 2034
  • Figure 7: North America Bleeding Disorders Testing Market Value Share (%), by Product Type, 2025
  • Figure 8: North America Bleeding Disorders Testing Market Value (USD million), by Indication, 2025 & 2034
  • Figure 9: North America Bleeding Disorders Testing Market Value Share (%), by Indication, 2025
  • Figure 10: North America Bleeding Disorders Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 11: North America Bleeding Disorders Testing Market Value Share (%), by End-user, 2025
  • Figure 12: North America Bleeding Disorders Testing Market Value (USD million), By Country, 2025 & 2034
  • Figure 13: North America Bleeding Disorders Testing Market Value Share (%), By Country, 2025
  • Figure 14: Europe Bleeding Disorders Testing Market Value (USD million), by Product Type, 2025 & 2034
  • Figure 15: Europe Bleeding Disorders Testing Market Value Share (%), by Product Type, 2025
  • Figure 16: Europe Bleeding Disorders Testing Market Value (USD million), by Indication, 2025 & 2034
  • Figure 17: Europe Bleeding Disorders Testing Market Value Share (%), by Indication, 2025
  • Figure 18: Europe Bleeding Disorders Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 19: Europe Bleeding Disorders Testing Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Bleeding Disorders Testing Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Bleeding Disorders Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Bleeding Disorders Testing Market Value (USD million), by Product Type, 2025 & 2034
  • Figure 23: Asia Pacific Bleeding Disorders Testing Market Value Share (%), by Product Type, 2025
  • Figure 24: Asia Pacific Bleeding Disorders Testing Market Value (USD million), by Indication, 2025 & 2034
  • Figure 25: Asia Pacific Bleeding Disorders Testing Market Value Share (%), by Indication, 2025
  • Figure 26: Asia Pacific Bleeding Disorders Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Bleeding Disorders Testing Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Bleeding Disorders Testing Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Bleeding Disorders Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Rest of the World Bleeding Disorders Testing Market Value (USD million), by Product Type, 2025 & 2034
  • Figure 31: Rest of the World Bleeding Disorders Testing Market Value Share (%), by Product Type, 2025
  • Figure 32: Rest of the World Bleeding Disorders Testing Market Value (USD million), by Indication, 2025 & 2034
  • Figure 33: Rest of the World Bleeding Disorders Testing Market Value Share (%), by Indication, 2025
  • Figure 34: Rest of the World Bleeding Disorders Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 35: Rest of the World Bleeding Disorders Testing Market Value Share (%), by End-user, 2025
  • Figure 36: Global Bleeding Disorders Testing Market Share (%), By Company, 2025